[CD7, HLA-DR, CD38 positive acute undifferentiated leukemia with subcutaneous tumor and thymoma].
A case of acute undifferentiated leukemia (AUL), accompanied by subcutaneous tumor and thymoma is reported. The analysis of immunophenotype showed that the leukemic blasts were positive for CD7, HLA-DR, CD38 and CD34 in 17.5% but negative results were obtained for other lymphoid and myeloid antigens. The leukemic blasts had a rearranged immunoglobulin heavy chain (IgH) gene and T cell receptor delta (TCR-delta) chain gene chromosomal abnormality, 47, XY, +8, t(13; 17) (q12; q21), -17, +M was observed. In general, the CR rate is low and prognosis is poor in patients with AUL. In our case, CR was not achieved by the therapy with JALSG-ALL87 protocol, but was achieved by subsequent treatment with high dose ara-C therapy and combination chemotherapy including intermediate-dose ara-C, mitoxantrone, etoposide and prednisolone.
Doi
T
T
Forth Department of Internal Medicine, Sapporo Medical University.
Sakamaki
S
S
Koike
K
K
Matsunaga
T
T
Kobayashi
D
D
Muramatsu
H
H
Sato
T
T
Watanabe
N
N
Kougo
Y
Y
Niitsu
Y
Y
D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000208:Acute Disease; D015703:Antigens, CD; D019011:Antigens, CD7 / Q000032:analysis*; D000943:Antigens, Differentiation / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D015321:Gene Rearrangement; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D016130:Immunophenotyping; D007938:Leukemia / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D008562:Membrane Glycoproteins; D008942:Mitoxantrone / Q000008:administration & dosage; D009699:N-Glycosyl Hydrolases / Q000032:analysis*; D011239:Prednisolone / Q000008:administration & dosage; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000235:genetics; D012074:Remission Induction; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D013945:Thymoma / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D013953:Thymus Neoplasms / Q000150:complications / Q000188:drug therapy / Q000276:immunology*
D015703:Antigens, CD; D019011:Antigens, CD7; D000943:Antigens, Differentiation; D006684:HLA-DR Antigens; D007143:Immunoglobulin Heavy Chains; D008562:Membrane Glycoproteins; D016692:Receptors, Antigen, T-Cell, gamma-delta; D003561:Cytarabine; D005047:Etoposide; D011239:Prednisolone; D008942:Mitoxantrone; D009699:N-Glycosyl Hydrolases; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1